U.S. markets closed

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7300-0.0100 (-1.35%)
At close: 04:00PM EDT
0.7300 0.00 (0.00%)
After hours: 04:49PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600

Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Mr. Ronald A. Andrews Jr.Pres, CEO & Director801.84kN/A1960
Dr. Douglas T. Ross M.D., Ph.D.Chief Science Officer558.94kN/A1960
Mr. Mitchell S. LevineCorp. Devel. Officer480.71kN/A1960
Ms. Gisela A. PaulsenCOO & PresN/AN/A1966
Mr. Anish JohnChief Financial OfficerN/AN/A1970
Mr. James LiuController & Principal Accounting OfficerN/AN/A1995
Dr. Ekkehard Schutz M.D., Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. William AnnettAdvisorN/AN/A1954
Mr. Robert S. SeitzHead of Immune OncologyN/AN/A1964
Dr. Michael D. West Ph.D.Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.N/AN/A1953
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Corporate Governance

OncoCyte Corporation’s ISS Governance QualityScore as of September 28, 2022 is 4. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.